Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERDICT: Optimal Treatment Target in Active Ulcerative Colitis
NCT04259138Phase 4Completed
- Sponsor
- Alimentiv Inc.
- Start
- Feb 2020
- Primary completion
- Apr 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 4, randomised, open-label trial of vedolizumab in ulcerative colitis (UC) (3 arms), sponsored by Alimentiv Inc. Primary endpoint: Difference in Time to UC-related Complication Between Treatment Target Groups 1 and 3. Started Feb 2020; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04259138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04259138.